Patent · US Active

6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes

US11179399B2 · kind B2 · utility

2Cited by

1References

36Claims

0Family size

Assignee

Sprint Bioscience AB · SE

Inventors

Jessica Martinsson · Sollentuna, SE
Martin Andersson · Huddinge, SE
Johan Lindström · Huddinge, SE
Rickard Forsblom · Tullinge, SE
Fredrik Rahm · Huddinge, SE
Tobias Ginman · Tullinge, SE
Jenny Viklund · Kungshättan, SE

Key dates

Filing date	Feb 17, 2017
Grant date	Nov 23, 2021
Priority date	—
Expiry date	Feb 17, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides novel 6-heterocyclyl-4-morpholin-4-yl-pyridine-2-one compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for using such compounds in treatment of diseases including cancer, diabetes, inflammatory disease, neurodegenerative disorders, cardiovascular disorders and viral infections; wherein R1, R2, R3 and A are as defined in the specification.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.